budesonide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 20 Diseases   17 Trials   17 Trials   3666 News 


«12...1011121314151617181920...4243»
  • ||||||||||  Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
    VEDOLIZUMAB FOR REFRACTORY MICROSCOPIC COLITIS: A CASE SERIES () -  Jan 28, 2022 - Abstract #CCCongress2022CCCongress_380;    
    Some patients suffer severe symptoms despite maximum dosage of budesonide, in these cases biologic therapies should be considered...The third patient was transitioned from vedolizumab to adalimumab and is now well controlled symptomatically and the final patient has not reached symptomatic remission of her disease...Due to low volume studies, the data supporting vedolizumab use in refractory microscopic colitis remains limited, and further studies are needed to elucidate the its potential as a first-line therapy. However, based on our experience, we recommend considering vedolizumab for patients suffering from refractory MC.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  New Strategies for Improving Budesonide Skin Retention. (Pubmed Central) -  Jan 26, 2022   
    When the hydrogels were formulated with the inclusion complex, an increase in budesonide skin retention was observed with both hydrogels. Poloxamer hydrogel proved to be a suitable vehicle for cutaneous administration of budesonide.
  • ||||||||||  budesonide / Generic mfg.
    Review, Journal:  Evidence-based treatments for eosinophilic esophagitis: insights for the clinician. (Pubmed Central) -  Jan 26, 2022   
    Finally, endoscopic dilation should be considered in patients with reduced esophageal caliber or persistent dysphagia despite histological remission. This article provides a state-of-the-art review and updated discussion of current therapies and newly developed options for EoE.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course. (Pubmed Central) -  Jan 18, 2022   
    Patients with eosinophilic gastroenteritis may be characterized into 2 forms. Patients with weight loss at time of presentation, hypoalbuminemia at presentation, serosal disease involvement, or anemia at diagnosis were associated with a chronic disease course requiring chronic medications.
  • ||||||||||  budesonide / Generic mfg.
    Also budesonide (Twitter) -  Jan 14, 2022   
  • ||||||||||  budesonide / Generic mfg.
    Review, Journal:  Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link. (Pubmed Central) -  Jan 13, 2022   
    Knowledge of antigen-mucosal interactions is now being successfully leveraged for therapeutic purposes; the gut-directed drug Nefecon (targeted release formulation-budesonide) is on track to become the first medication to be approved specifically for the treatment of IgAN. In this review, we examine established immunological paradigms in IgAN, explore how antigen-mucosal immune responses drive disease, and discuss how this knowledge is being used to develop new treatments.
  • ||||||||||  Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
    Journal:  P053 Interstitial Nephritis from IBD: Complicated Conclusions. (Pubmed Central) -  Jan 11, 2022   
    TIN secondary to aminosalicylates is well-documented, but there are few reports of adalimumab-induced granulomatous TIN and only one report of vedolizumab-induced TIN. Each of our patients had well-controlled IBD and multiple confounding variables that could impact kidney function or cause TIN, including hypertension and multiple potential culprit medications, illustrating the dilemma of determining the etiology of renal injury in IBD patients.